<DOC>
	<DOCNO>NCT00100308</DOCNO>
	<brief_summary>The purpose study determine whether low dose continuous infusion unfractioned heparin ( 500 units/hour ) , addition standard treatment , efficacious complementary therapy sepsis patient .</brief_summary>
	<brief_title>Unfractioned Heparin Treatment Sepsis</brief_title>
	<detailed_description>Sepsis consider leading cause death worldwide approximately 18 million case annually mortality rate almost 30 % . The search efficacious therapeutic approach largely fail recent intervention , activate protein C low dose steroid , show success improve survival . However , intervention test patient severe sepsis and/or septic shock although group exhibit high mortality , represent le 50 % total affected population . Furthermore , intervention necessitate special device , test and/or drug might unavailable simply unaffordable resource-limited setting . Animal human model suggest heparin , addition successfully inhibit coagulation cascade , may also modulate wide array response infection . Furthermore , three clinical trial recombinant anticoagulant allow use prophylactic treatment venous thrombosis dose unfractioned heparin ( UFH ) 10,000 15,000 unit subcutaneously per day . When receive heparin compare placebo arm clinical trial , three study show high mortality subgroup receive heparin . Although randomized comparison , constant result three different study population variable entry criterion , along natural heterogeneity illness , strongly foster hypothesis heparin might reduce , beyond know anticoagulant antithrombotic property , overall mortality sepsis . In project , propose phase II/III , randomize , double-masked , placebo-controlled , single-center clinical trial total sample size 310 patient , test low dose continuous infusion UFH ( 500 units/hour ) 7 day , complementary treatment septic patient . Our primary aim estimate effect UFH length stay change baseline Multiple Organic Dysfunction ( MOD ) score . Secondary objective estimate effect UFH 28-day all-cause mortality , estimate possible effect-modification 28-day all-cause mortality , subgroup define site infection baseline value APACHE II score , MOD score D-dimer .</detailed_description>
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Toxemia</mesh_term>
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>Patients must infection defined clinical and/or microbiological criterion accordance modify CDC definition nosocomial infection Patients must present one GENERAL VARIABLES , AND one INFLAMMATORY VARIABLES within 24 hour admission study GENERAL VARIABLES : Temperature ( oral axillary ) &gt; 38ºC &lt; 36ºC , Heart rate &gt; 90 beats/min , Respiratory rate &gt; 20 breaths/min , Altered mental status determine Glasgow Coma Scale &lt; 15 , Systolic blood pressure &lt; 90 mm Hg decrease &gt; 40 mm Hg INFLAMMATORY VARIABLES : WBC &gt; 12,000 μL1 &lt; 4,000 μL1 &gt; 10 % immature form , Plasma Creactive protein &gt; 5 mg/dL . These variable attributable underlying disease infection due effect concomitant therapy . Pregnant breastfeeding . Platelet count &lt; 60,000/mm3 . Increased risk bleeding : * Any patient undergone major surgery , define surgery require general spinal anesthesia , perform within 12hour period immediately precede admission hospital ; postoperative patient demonstrate evidence active bleeding ; patient plan anticipated major surgery first 12 hour admission hospital . * History : severe head trauma require hospitalization , intracranial surgery , stroke within 3 month study entry ; history intracerebral arteriovenous malformation , cerebral aneurysm , central nervous system mass lesion . * History congenital bleeding diatheses , hemophilia . * Gastrointestinal bleeding within 6 week study entry require medical intervention unless definitive surgery perform . * Trauma patient increase risk bleeding , example : flail chest ; significant contusion lung , liver , spleen ; retroperitoneal bleed ; pelvic fracture ; compartment syndrome . Patients know hypercoagulable condition include activate Protein C resistance ; hereditary deficiency Protein C , Protein S , antithrombin ; presence anticardiolipin antibody , antiphospholipid syndrome , lupus anticoagulant homocysteinemia ; patient recently document ( within 3 month study entry ) highly suspect deep venous thrombosis pulmonary embolism . Patients take require follow medication : * Therapeutic heparin , define UFH dose treat active thrombotic embolic event within 12 hour prior study entry LMWH use dose higher frequent recommend dose product label prophylaxis within 12 hour prior study entry . * Warfarin , use within 7 day study entry . * Thrombolytic treatment within 3 day study entry ( example , streptokinase , rtPA , urokinase ) . * Glycoprotein IIb/IIIa antagonist within 7 day study entry . Patients know esophageal varix , chronic jaundice , cirrhosis , chronic ascites . Patients expect survive 28 day give preexisting , uncorrectable medical condition . This criterion include patient , suspect , poorly control neoplasms endstage process , endstage cardiac disease , prior cardiac arrest , endstage lung disease , endstage liver disease . Patients chronic renal failure either hemodialysis peritoneal dialysis . HIV positive patient recent CD4 count &lt; 200/mm3 . Patients undergone bone marrow , liver , lung , kidney pancreas transplantation . Inability unwillingness patient legal representative give write informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>sepsis</keyword>
	<keyword>Randomized clinical trial</keyword>
	<keyword>Heparin</keyword>
	<keyword>Therapy</keyword>
</DOC>